Staphylococcus aureus (S. aureus) biofilm is the major cause of failure of implant infection treatment that results in heavy social and economic burden on individuals, families, and communities. Planktonic S. aureus attaches to medical implant surfaces where it proliferates and is wrapped by extracellular polymeric substances, forming a solid and complex biofilm. This provides a stable environment for bacterial growth, infection maintenance, and diffusion and protects the bacteria from antimicrobial agents and the immune system of the host. Macrophages are an important component of the innate immune system and resist pathogen invasion and infection through phagocytosis, antigen presentation, and cytokine secretion. The persistence, spread, or clearance of infection is determined by interplay between macrophages and S. aureus in the implant infection microenvironment. In this review, we discuss the interactions between S. aureus biofilm and macrophages, including the effects of biofilm-related bacteria on the macrophage immune response, roles of myeloid-derived suppressor cells during biofilm infection, regulation of immune cell metabolic patterns by the biofilm environment, and immune evasion strategies adopted by the biofilm against macrophages. Finally, we summarize the current methods that support macrophage-mediated removal of biofilms and emphasize the importance of considering multi-dimensions and factors related to implant-associated infection such as immunity, metabolism, the host, and the pathogen when developing new treatments.
Background: This study aimed to delineate the cell heterogeneity in the bone-implant interface and investigate the fibroblast responses to implant-associated S. aureus infection. Methods: Single-cell RNA sequencing of human periprosthetic tissues from patients with periprosthetic joint infection (PJI, n = 3) and patients with aseptic loosening (AL, n = 2) was performed. Cell type identities and gene expression profiles were analyzed to depict the single-cell landscape in the periprosthetic environment. In addition, 11 publicly available human scRNA-seq datasets were downloaded from GSE datasets and integrated with the in-house sequencing data to identify disease-specific fibroblast subtypes. Furthermore, fibroblast pseudotime trajectory analysis and Single-cell regulatory network inference and clustering (SCENIC) analysis were combined to identify transcription regulators responsible for fibroblast differentiation. Immunofluorescence was performed on the sequenced samples to validate the protein expression of the differentially expressed transcription regulators. Results: Eight major cell types were identified in the human bone-implant interface by analyzing 36,466 cells. Meta-analysis of fibroblasts scRNA-seq data found fibroblasts in the bone-implant interface express a high level of CTHRC1. We also found fibroblasts could differentiate into pro-inflammatory and matrix-producing phenotypes, each primarily presented in the PJI and AL groups, respectively. Furthermore, NPAS2 and TFEC which are activated in PJI samples were suggested to induce pro-inflammatory polarization in fibroblasts, whereas HMX1, SOX5, SOX9, ZIC1, ETS2, and FOXO1 are matrix-producing regulators. Meanwhile, we conducted a CMap analysis and identified forskolin as a potential regulator for fibroblast differentiation toward matrix-producing phenotypes. Conclusions: In this study, we discovered the existence of CTHRC1+ fibroblast in the bone-implant interface. Moreover, we revealed a bipolar mode of fibroblast differentiation and put forward the hypothesis that infection could modulate fibroblast toward a pro-inflammatory phenotype through NPAS2 and TFEC.
The virulence factors of Staphylococcus aureus are tightly controlled by two-component systems (TCSs) and small RNA (sRNA). TCSs have been well studied over the past several decades, but our understanding of sRNA functions lags far behind that of TCS functions. Here, we studied the biological role of sRNA from 506 S. aureus RNA-seq datasets using independent component analysis (ICA). We found that a previously neglected sRNA, Sau-41, functions in the Agr system. Sau-41 is located within the PSMα operon and controlled by the Agr system. It was predicted to share 22-base complementarity with RNAIII, a major regulator of S. aureus virulence. The EMSA results demonstrated that Sau-41 directly binds to RNAIII. Furthermore, our results found that Sau-41 is capable of repressing S. aureus haemolysin activity by downregulating α-haemolysin and δ-toxin. The repression of α-haemolysin was attributed to the competition between the 5’ UTR of hla and Sau-41 for binding RNAIII. We observed that Sau-41 mitigated S. aureus virulence in an orthopaedic implant infection mouse model and alleviated osteolysis. Together, our results indicate that Sau-41 is a virulence-regulating RNA and suggest that Sau-41 might be involved in a negative feedback mechanism to control the Agr system. This work is a demonstration of using ICA in sRNA identification by mining high-throughput data and could be extended to other organisms as well.
Staphylococcus aureus can form aggregates within human synovial fluid, contributing to joint infections that are resistant to conventional therapies. However, the regulatory pathways underlying this process remain unclear. Here, we reveal that the S. aureus two-component system saeRS contributes to synovial aggregation by controlling the expression of fibrinectin-binding proteins A and B (FnbA/B), which bind to human fibrinogen and cause aggregation. We further demonstrate that the fatty acid kinase (fak) system is the primary regulator for SaeS activity under host conditions. Mechanistically, fak is epistatic to saeRS by scavenging exogenous fatty acids and altering the localization of SaeS into functional membrane microdomains (FMMs), which are essential for SaeS function. We also identify that undecanoic acid (UDA) is capable of inhibiting the fak pathway, demonstrating its efficacy and potential applicability in treating joint infections. Altogether, these findings highlight the fak-saeRS axis as a potential therapeutic target for joint infections and underscore UDA as a promising treatment for these infections.
Metabolism alterations significantly influence the behavior of both bacteria and immune cells in the microenvironment of diabetes‐associated biofilm infections, ultimately determining the outcome of infections. Here, we propose a dual‐target nano‐metabolic therapy based on a biomimetic nanoplatform to combat these infections. The nanoplatform, coated with cellular membranes from pre‐infected macrophages and loaded with glucose oxidase (GOx) and L‐arginine (Arg), facilitates targeted drug delivery. Nitric oxide (NO), generated in situ through the catalytic cascade reaction of GOx and Arg, acts as a dual‐target metabolic regulator. It disrupts bacterial carbon and nitrogen metabolism, particularly the tricarboxylic acid (TCA) cycle and amino acid metabolism, effectively eliminating biofilms. Simultaneously, NO modulates macrophage metabolism, shifting it from oxidative phosphorylation to aerobic glycolysis by suppressing TCA cycle enzymes and electron transport chain complexes, while preserving mitochondrial integrity. This energy metabolism transition reverses macrophage immunosuppression, enhancing their phagocytic and invasive functions to promote infection clearance. Experiments with multiple clinical bacterial strains and various diabetic infection models highlight the therapeutic potential of combining metabolism interference with immune modulation, offering new insights for the treatment of diabetes‐associated biofilm infections.
Background: Implant-associated infections caused by Staphylococcus aureus biofilms remain difficult to eradicate because the extracellular matrix and metabolic heterogeneity jointly suppress antibiotic penetration and immune clearance. The biofilm environment induces excessive interleukin-10 (IL-10) production in dendritic cells, leading to inhibition of the cGAS–STING signaling pathway and T-cell activation. Therefore, strategies that simultaneously disrupt biofilm structure and reverse the immunosuppressive microenvironment are urgently needed. Results: We developed a near-infrared–responsive MnO₂@PMS nanoregulator that integrates photothermal catalysis with metabolic immunotherapy. Upon laser irradiation, MnO₂@PMS generated oxygen-independent sulfate radicals (•SO₄⁻) that efficiently degraded the biofilm matrix and suppressed bacterial glutamate metabolism, thereby reducing the synthesis of poly-γ-glutamic acid. This metabolic inhibition decreased biofilm-derived glutamate accumulation and downregulated IL-10 production in dendritic cells, leading to reactivation of the cGAS–STING pathway and restoration of antigen presentation. In vivo, MnO₂@PMS treatment promoted mature dendritic-cell and T-cell activation, reduced bacterial burden, alleviated local inflammation, and enhanced angiogenesis and tissue repair, while exhibiting favourable short-term biocompatibility in vivo. Conclusions: This study introduces a glutamate-targeted nanoplatform that couples biofilm destruction with immune reprogramming in a chronic biofilm infection model. By bridging metabolic regulation and immune activation, MnO₂@PMS complements existing nanozyme and photothermal antibiofilm strategies by illustrating a mechanistically supported approach that integrates oxygen-independent sulfate radical catalysis with modulation of glutamate–IL-10–associated immunosuppression.